{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000335","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.456841+00:00","generated_at":"2026-06-05T01:44:24.651678+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcturus FY2023 revenue $169.9M, net loss $26.6M; cash runway extended to Q1 2027","bullets":["FY2023 revenue $169.9M (down from $206.0M); net loss $26.6M ($1.00 diluted EPS) vs prior year net income $9.3M ($0.35 EPS).","Q4 2023 revenue $34.0M (down from $160.3M in Q4 2022, which included $200M CSL upfront); Q4 net loss $8.6M ($0.32 diluted EPS).","Cash and equivalents $348.9M; cash runway extended to Q1 2027; total CSL milestones received $396M.","Kostaive (sa-mRNA COVID vaccine) approved in Japan, launch expected in 2024; ARCT-032 Phase 1b interim data expected Q2 2024.","New STARR vaccine discovery programs for Lyme disease and gonorrhea initiated; ARCT-2138 (LUNAR-FLU) Phase 1 study started."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000335","json":"https://secwatch.observer/filing/0001193805-24-000335.json","markdown":"https://secwatch.observer/filing/0001193805-24-000335.md","text":"https://secwatch.observer/filing/0001193805-24-000335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/0001193805-24-000335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/e619328_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:44:24.651678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00b104b9d9b85339c77e2bbe4ebd3593c15639fd","claim":"Arcturus Therapeutics Holdings Inc. reported the three months ended December 31, 2023 results: revenue $34.0 million.","evidence_excerpt":"For the three months ended December 31, 2023, revenue recognized was $34.0 million compared with $160.3 million for the three months ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/0001193805-24-000335-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Revenue","value":"$34.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"35a5f56db04f8993d88cfb6a3cdb75ba38ebcde7","claim":"Arcturus Therapeutics Holdings Inc. reported the year ended December 31, 2023 results: revenue $169.9 million.","evidence_excerpt":"For the year ended December 31, 2023, we reported revenue of $169.9 million compared with $206.0 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/0001193805-24-000335-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$169.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}